Amima Mahmood, PharmD Candidate 2023, and Deborah Wagner, PharmD, FASHP, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Nathaniel Hunt, MD, James A. Cranford, PhD, Stacey Noel, MD, and Christine Brent, MD, Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
J Pain Palliat Care Pharmacother. 2023 Jun;37(2):133-142. doi: 10.1080/15360288.2023.2169433. Epub 2023 Jan 30.
Prior to 2020, pain management in the Washtenaw/Livingston County Medical Control Authority (W/L MCA) Emergency Medical Service (EMS) system in Southeast Michigan was limited to morphine, fentanyl, ketorolac, and acetaminophen. Based on the increasing evidence describing its safety and efficacy, ketamine was added to local protocols for pain management. This study aimed to evaluate differences in pain management and adverse effects of ketamine and opioid administration. Data from pediatric patients who received ketamine or an opioid in the W/L MCA EMS system from October 2019 to March 2021 were analyzed. The primary outcome was the difference in pain score, and the secondary outcome was adverse effects observed after analgesic administration. The decrease in pain scores was greater among ketamine patients (mean: 5.2) compared to opioid patients (mean: 2.9), < 0.001. The prevalence of adverse effects was higher among patients in the ketamine group (28.6%) compared to patients in the opioid group (2.4%, < 0.001). Of 14 patients who received ketamine, one 17-year-old male experienced mild anxiety (7.1%), two teenage females experienced mild dissociation (14.3%), and one 20-year-old female experienced mild nausea (7.1%). Overall, ketamine is a safe and effective option compared to opioids for pediatric patients experiencing moderate to severe prehospital pain.
在 2020 年之前,密歇根州东南部的 Washtenaw/Livingston 县医疗控制局(W/L MCA)急诊医疗服务(EMS)系统中的疼痛管理仅限于吗啡、芬太尼、酮咯酸和对乙酰氨基酚。基于越来越多的安全性和有效性证据,氯胺酮被添加到当地的疼痛管理方案中。本研究旨在评估氯胺酮和阿片类药物给药在疼痛管理和不良反应方面的差异。分析了 2019 年 10 月至 2021 年 3 月期间在 W/L MCA EMS 系统中接受氯胺酮或阿片类药物的儿科患者的数据。主要结果是疼痛评分的差异,次要结果是镇痛给药后观察到的不良反应。与阿片类药物组(平均:2.9)相比,氯胺酮组患者的疼痛评分下降更大(平均:5.2),<0.001。氯胺酮组患者不良反应的发生率(28.6%)高于阿片类药物组(2.4%),<0.001。在接受氯胺酮的 14 名患者中,1 名 17 岁男性出现轻度焦虑(7.1%),2 名青少年女性出现轻度分离(14.3%),1 名 20 岁女性出现轻度恶心(7.1%)。总体而言,与阿片类药物相比,氯胺酮是一种安全有效的选择,可用于经历中度至重度院前疼痛的儿科患者。